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clearly needs to be further defined (Bunz
et al., 1998; Wouters et al., 1999).
The current studies also provide a
framework for why mutations only affect-
ing the apoptotic pathway do not neces-
sarily correlate with a poor prognosis.
These mutations might have prevented
the occurrence of other lesions, such as
in p53, which are in fact more harmful
because they could mitigate the efficacy
of anticancer agents. The observations
reported in these two papers (Schmitt et
al., 2002a, 2002b) also argue that the
genomic instability that is concurrent
with p53 deficiency in this system does
not significantly contribute to tumor initia-
tion and progression but rather is an
accidental side effect that nevertheless
may have major consequences for the
efficacy of subsequent treatment.
The obvious question that remains is
how senescence plays out against apop-
tosis and mitotic catastrophe in the erad-
ication of various tumors by anticancer
agents. The CTX-induced senescence
was most pronounced in the absence of
apoptosis. Hence, the relative role of
senescence in drug treatment sensitivity
likely depends on the cell type, the
genetic lesions that drove tumor devel-
opment, and last but not least, the anti-
cancer agent itself. Studies in other sys-
tems support this (Bunz, 1999).
Therefore, we must understand the inter-
play between these lesions and their
impact on the various resistance mecha-
nisms. Only then can we offer patients—
after appropriate molecular characteriza-
tion of the tumor—the tailored treatment
that takes into account tumor-specific
resistance mechanisms similar to those
described by Lowe and collaborators.
Induction of senescence offers at least
an appealing new option to include as a
strategy for intervention.
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The p53 tumor-suppressor protein, first
identified in 1979, acts as a major node
in a complex network evolved to sense
diverse cellular stresses including DNA
damage and hyperproliferative signals
(Ko and Prives, 1996). Once stabilized
and activated by genotoxic stress, p53
can either activate or repress a wide
array of different gene targets, which in
turn can regulate cell cycle, cell death,
DNA repair, angiogenesis, and other out-
comes. p53 functions, including apopto-
sis, are thought to require its sequence-
specific DNA binding and transcriptional
activation activities, and a number of
apoptosis-related genes are induced by
p53 activation (Johnstone et al., 2002).
Consequently, p53 is reported to be
functionally inactivated in more than half
of all human tumors, and murine models
have confirmed p53’s central role in
tumorigenesis. Furthermore, the majority
of tumor-associated p53 mutations occur
in the core DNA binding domain and pre-
vent interaction with target sequences.
The cloning in the late 1990s of two p53-
related genes, p63 and p73, caused a
great excitement within the cancer biolo-
gy community with the prospect of two
additional tumor suppressors (Yang and
McKeon, 2000). Initially the family
resemblance was striking. p63 and p73
share with p53 an amino-terminal trans-
p53 leans on its siblings
Despite the common assumption that p53 by itself can induce apoptosis, results of a recent study implicate the homolo-
gous genes p63 and p73 in p53-mediated programmed cell death.
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activation domain and a highly con-
served central DNA binding domain, as
well as a carboxy-terminal tetrameriza-
tion domain. Moreover, at least in overex-
pression assays, p63 and p73 were
shown to transactivate many p53 target
genes including p21/WAF-1 and Bax,
and they were able to induce cell cycle
arrest and apoptosis (Yang and McKeon,
2000).
In screening for tumor-associated
mutations, the siblings began to differen-
tiate themselves. Multiple reports failed
to show that inactivating p63 or p73
mutations in a wide variety of tumor
types were as common as in p53.
Furthermore, mouse knockout studies
indicated that loss of p73 or p63 did not
predispose to cancer (Yang and
McKeon, 2000). Thus, despite their
strong family resemblance, it appeared
that p53, p63, and p73 were not acting
simply as redundant tumor suppressors.
However, a recent landmark paper
from Tyler Jacks’ laboratory reunites the
p53 family (Flores et al., 2002). To inves-
tigate the role of p63 and p73 in p53-
induced apoptosis, the Jacks group uti-
lized a series of mouse embryo fibrob-
lasts (MEFs) lacking either p63 or p73
singly or double-knockout cells lacking
both p63 and p73 but retaining p53.
Building on a previous model showing
that adenovirus E1a-expressing MEFS
are predisposed to apoptosis when sub-
jected to DNA damage (Lowe et al.,
1993), treatment of these cells with dox-
orubicin revealed that cells lacking p63
or p73 alone showed an intermediate
resistance to apoptosis between that of
p53 null and wild-type MEFs. Most inter-
esting is their observation that p63−/−
;p73−/− double null cells were equally
resistant to apoptosis as p53−/− MEFS,
suggesting that p63 and p73 are
required for p53-induced apoptosis. The
same observation was made by examin-
ing apoptosis in the central nervous sys-
tem of single- or double-knockout
embryos following γ irradiation. Thus,
p53 may be more dependent on its sib-
lings than previously thought.
Following DNA damage, p53 is stabi-
lized as a result of release from its nega-
tive regulator, the Mdm2 E3 ubiquitin lig-
ase (Michael and Oren, 2002). Western
blotting of the MEFs revealed that stabi-
lization of p53 as well as p63 occurs nor-
mally in single- and double-null MEFs
following doxorubicin treatment, indicat-
ing that in the absence of p63, p73, or
both, factors functioning upstream of the
p53 family are intact and that faulty
upstream signaling cannot explain the
drug resistance of p63−/−;p73−/− cells.
As stabilization of p53 in the
absence of p63 and p73 was found to be
intact, the logical next step was to
assess transcriptional activation within
the p53 family MEF system. These
experiments revealed striking differ-
ences in the activity of p53 when it lacks
the support of the family members.
Induction of p21/WAF-1, indispensable
for p53-induced cell cycle arrest and
mdm-2, important in the regulation of
p53 protein levels, occurred normally in
p63−/−, p73−/−, and double-null MEFs.
Remarkably, however, loss of p63 and
p73 severely affected the induction of
bax and PERP, two genes thought to
mediate p53-dependent apoptosis. This
suggests that p53 target genes are dif-
ferentially affected by the loss of p63 and
p73 and that apoptosis-related targets
may be specifically regulated within the
entire p53 family.
To further characterize the mecha-
nism of target gene disparity, the Jacks
group performed chromatin immunopre-
cipitation (ChIP) assays to examine pro-
moter element binding in vivo by p53 and
p63. Indeed, following doxorubicin treat-
ment, p53 was still bound to the p21 and
mdm-2 promoters but did not engage
with promoter elements of the apoptosis-
related genes bax, PERP, or NOXA.This
suggests that for certain genes, p63 and
p73 are required for stable p53 promoter
binding. Interestingly, ChIP analysis in
p53−/− MEFs showed that p63 still bound
to promoter sequences for bax, PERP,
and NOXA. This strengthens the notion
that the p63/p73 gene products are
important for p53-dependent apoptosis
but that if bax, PERP, and/or NOXA are
necessary for apoptosis, binding by p63
alone is not sufficient. Moreover, in p53−/−
MEFs, basal levels of all p53 target
genes tested fall below detectable levels,
suggesting reciprocally that p63 and p73
cannot transactivate certain target genes
without p53’s support. Taken together,
these results demonstrate essential
roles for p63 and p73 in p53-mediated
apoptosis of MEFs and murine neuronal
cells and imply that the p53 homologs
work somehow to selectively stabilize
the interaction of p53 with promoters of
proapoptotic genes.
The results of Flores et al. pose
many questions and point the way for
future studies. Most intriguingly, the
mechanism by which p53 and its rela-
tives cooperate to produce cell death
upon DNA damage remains to be fully
elucidated. The authors’ data are most
consistent with p53 activating a single
Figure 1. Two models for the role of p63 and p73 in p53-dependent apoptosis
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apoptotic program that requires assis-
tance from p63/p73, which is supported
by their result that p53 binding to selec-
tive proapoptotic promoters in vivo is
abrogated in the absence of p63 and
p73. This in itself is a rather surprising
result because the most obvious expla-
nation, namely that p53 and its two sib-
lings can interact with each other to form
active cotetramers (thus producing a
larger pool of activator), is argued
against strongly by data showing that
stable cotetramers between p53 and p63
or p73 cannot form in vitro (Davison et
al., 1999) and that when overexpressed,
full-length wild-type p53 and either p63
or p73 cannot be coimmunoprecipitated
in vivo (Gaiddon et al., 2001).
Hence, to explain p53’s inability to
bind certain promoters in the absence of
p63 and p73, more indirect mechanisms
may be invoked. In vitro studies have
shown that p53 has relatively high on
and off rates for DNA binding, and
p53/DNA complexes can be stabilized by
protein-protein interactions. Thus, if
strong binding by p53 to some sites in
vivo requires extensive interaction with
other factors, then one could envisage
how p63 or p73 might play an indirect
role in stabilization and ultimately in p53
apoptotic function. In one possible sce-
nario, “the dynamic exchange model,”
p63 and/or p73 reside with p53 in a larg-
er transcriptional complex in which either
p53 or a sibling may engage the promot-
er element at any given moment. In this
capacity, p63 and p73 may function to
stabilize the complex but also may favor
promoter activation by increasing the
probability that an active tetramer is
bound to the response element (Figure
1A).
An alternative model posits a
requirement for two discrete binding
sites within a target gene promoter
(Figure 1B). Engagement of two or more
such response elements by p53 and/or
p63 and p73 within a single promoter
may be required for maximal induction of
transcription through stabilization of the
association between DNA and p53 fami-
ly proteins as well as complete recruit-
ment of transcriptional machinery and
other cofactors (Figure 1B). In fact, a
number of p53 proapoptotic target pro-
moters have been reported to possess at
least two discrete widely spaced p53
binding sites such as Bax (Miyashita and
Reed, 1995) and PERP (Attardi et al.,
2000). Intriguingly, another proapoptotic
gene, PIG3, was recently reported to be
activated by p53 through a microsatellite
sequence within its UTR distinct from its
previously reported classical p53 con-
sensus sequence, suggesting the exis-
tence of alternate modes of DNA binding
and transcriptional regulation by p53
(Contente et al., 2002). Notably as well,
Flores et al. indicated that their analysis
of the PERP promoter suggested that
p53 and p63 each engage most strongly
with distinct promoter elements. This
may represent an additional mechanism
for p63 and p73 involvement in the induc-
tion of apoptosis. Nevertheless, having
one versus two binding sites cannot be
the sole defining factor for whether or not
a promoter requires all p53 family mem-
bers, since numerous additional genes,
including p21 (el-Deiry et al., 1995), pos-
sess two discrete p53 binding sites, and
p21 was shown by Flores et al. to be
induced in the absence of p63 and p73.
Whatever the mechanism, the data pre-
sented by the Jacks group suggests that
promoters vary in their levels of need for
p63 or p73.
In addition to elucidating the means
by which p63 and p73 facilitate apoptosis
by p53, many questions remain to be
addressed. Since there are multiple iso-
forms expressed by p63 and p73 which
differ at their N and C termini, what are
the domains of p63 or p73 proteins that
are required to facilitate p53-promoter
interactions? Do requirements for p53
family members vary with the source of
stress signal? In addition to their role in
apoptosis, do p63 and p73 have any part
in the ability of p53 to regulate cell cycle,
DNA repair, or angiogenesis? Finally,
loss of p63 and p73 has discrete effects
on certain tissue compartments: squa-
mous epithelia in the case of p63 and
neural cells for p73 (Yang and McKeon,
2000). Tumors of distinct histological ori-
gin may also show variations in p53 fam-
ily relations. Since p53 knockout mice do
not recapitulate the defects of family
member knockouts, p63 and p73 most
likely perform additional p53-indepen-
dent functions. What is the nature of
such functions, and how are they differ-
entially regulated by these different
genes?
Going forward, the paper by Flores
et al. is revolutionary in that these data
force us to consider p53 in the context of
its family more than ever before. While
this may add further complexity to an
already complicated area, we can take
comfort in the fact that p53 no longer
stands apart but rather is yet another
example of a truth we have long know
about family: you can’t live with them and
you can’t live without them.
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